EUCTR2008-004096-21-DE进行中（未招募）不适用
A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients = 18 years old with ability to take oral drugs
- •2. Diagnosis of advanced HCC according to the AASLD Guidelines (Bruix and Sherman 2005)
- •3. HCC stage B or C according to the Barcelona Clinic Liver Cancer (BCLC) (Llovet, et al 2008b)
- •4. No previous systemic therapy for HCC, (tamoxifen is allowed as previous systemic therapy)
- •5. Measurable disease according to RECIST, i.e. at least one measurable lesion. This lesion should not have been previously treated with local therapy. A treated lesion may be used where these lesions are the only lesions available for evaluation and have shown definite progression since their last local treatment. Local therapy must have been completed at least four weeks prior to baseline evaluation
- •6. Patients with ECOG performance status of 0 or 1 (see Section 7.5.4)
- •7. Cirrhotic status of current Child-Pugh class A only (5-6 points) with no encephalopathy and no ascites (ascites controlled by diuretics is also excluded in this study). Child-Pugh status should be calculated based on clinical findings and laboratory results during the screening period.
- •8. For patients with background chronic hepatitis B virus (HBV) (current or past infection), they must be treated with anti virals as prophylaxis at least 2 weeks prior to receiving study drug, Visit 2.
- •9. The following laboratory parameters at Visit 2:
- •Absolute Neutrophil Count (ANC) =1.5 x 109/L
- •Platelets = 70000 x 106/L
- •Hemoglobin (Hgb) = 9 g/dL
- •Serum aspartate aminotransferase (AST) and alanine amino-transferase (ALT) = 5 x ULN
- •Serum creatinine = 1.5 x ULN
- •10. Ability to understand and willingness to sign a written informed consent and to be able to follow the visit schedule
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients currently receiving any anti cancer therapy or who have received any local anti cancer therapy = 4 weeks prior to baseline CT/MRI scan, Visit 2
- •2. Active bleeding during the last 30 days prior to Visit 1 including variceal bleeding (Esophageal varices should be treated according to standard practice e.g. ligation/banding and procedure completed 30 days prior to Visit 1.)
- •3. Patients with a known hypersensitivity to RAD001 (everolimus) or known hypersensitivity to sorafenib or contradictions to sorafenib based on the local sorafenib label
- •4. Known previous/current malignancy requiring treatment within = 3 years except for cervical carcinoma in situ, basal cell carcinoma, and superficial bladder carcinoma 5. Known history of human immunodeficiency virus (HIV) seropositivity, (HIV testing is not mandatory)
- •6. Any severe and/or uncontrolled medical conditions including:
- •Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months prior to Visit 1, serious uncontrolled cardiac arrhythmia, uncontrolled hypertension
- •Previous TIA, CVA, symptomatic PVD within last 6 months of Visit 1
- •Patients with active alcohol intake
- •Uncontrolled diabetes as defined by HbA1c >8%
- •Greater or equal grade 3 hypercholesterolemia/hypertriglyceridemia or = grade 2 hypercholesterolemia/hypertriglyceridemia with history of coronary artery disease (despite lipid-lowering treatment if given)
- •Acute and chronic, active infectious disorders and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study therapy, in the opinion of the investigator, except chronic HBV or hepatitis C virus (HCV).
- •Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
- •Significant deterioration of lung function, defined as any of the following: 30% decrease in predicted lung volumes, and/or 30% decrease in DLCO, and/or = 88% O2 saturation at rest on room air
- •7. Patients receiving chronic treatment with corticosteroids (except for intermittent topical or
- •local injection or aldosterone) or another immunosuppressive agent
- •8. Patients treated with drugs known to be strong inhibitors or inducers of isoenzyme CYP3A (see Table 6-5) unless the drugs are medically necessary and no substitutes are available. If there are no acceptable substitutes, special precautions should be taken in these patients (see Section 6.5.8.8).
- •9. Patients who have undergone major surgery = 2 weeks prior to starting study drug or who have not recovered from surgery
- •10. Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control. Adequate contraceptives must be used throughout the trial and for 3 months after last study drug administration in both sexes. Women of childbearing potential must have a negative serum pregnancy test within 72 hours prior to administration of RAD001 and/or sorafenib.
- •11. Patients who have received an investigative drug or therapy within the last 30 days prior to Visit 1
- •12. Patients unwilling or unable to comply with the protocol, in the opinion of the investigator
研究者
相似试验
进行中（未招募）
1 期
A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma - NAadvanced hepatocellular carcinomaEUCTR2008-004096-21-NLovartis Pharma Services AG
尚未招募
不适用
A Phase I open label/ Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinomaliver cancer10019815Hepatocellular carcinomaNL-OMON32745ovartis15
招募中
2 期
A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer2024-515379-36-00Ability Pharmaceuticals S.A.98
招募中
不适用
Fase I/II study: RAD001 and sorafenib combination in patients with advanced hcc.hepatocellular carcinomaRAD001sorafenibeverolimusLeverkankerRAD001sorafenibeverolimusNL-OMON24345ovartis Pharma130
已完成
不适用
A phase I, open-label, randomized, two period, two-way cross over study to assess the influence of a high-calorie, high fat meal on the bioavailability of a 40 mg extended release PHA 022121 oral formulatioangioedemaNL-OMON53489Pharvaris Netherlands BV10